Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2a randomized double-blind sham-controlled dose-escalation study of PR001A in Parkinson's disease with GBA1 mutation
MOH_2020-05-04_008691Phase 2Not yet recruiting
- Sponsor
- Prevail Therapeutics Inc.
- Start
- Dec 2019
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LY3884961 in Parkinson's disease (PD) (3 arms), sponsored by Prevail Therapeutics Inc. Planned start Dec 2019; status: not yet recruiting.
02
Drugs
LY3884961
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on MOH_2020-05-04_008691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-05-04_008691.